Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract.
- Conditions
- Health Condition 1: null- Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract.Health Condition 2: C67- Malignant neoplasm of bladder
- Registration Number
- CTRI/2017/08/009196
- Lead Sponsor
- F HoffmanLa Roche Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 11
Signed informed consent form
Age more than 18 years
Histologically documented locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract
Patients with measurable and non-measurable disease according to RECIST v1.1 are allowed
Must have received one prior combination chemotherapy regimen for inoperable, locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract
Eastern Cooperative Oncology Group Performance Status 0, 1 or 2
Representative formalin-fixed paraffin-embedded tumor specimen block available for submission
Life expectancy more than 12 weeks
Adequate hematologic and end-organ function
Patients with treated, asymptomatic central nervous system metastases are eligible
For women of childbearing potential: agreement to remain abstinent or use contraceptive methods that result in a failure rate of less than 1 percent per year during the treatment period and for at least 5 months after the last dose of atezolizumab
Treatment with more than one prior line of systemic therapy for inoperable, locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract and any other investigational agent or participation in another clinical trial with therapeutic intent within 4 weeks prior to study treatment initiation
Treatment with chemotherapy within 2 weeks prior to study treatment initiation
Treatment with radiotherapy ongoing at the time of study entry (for CNS-directed radiotherapy, please refer to Inclusion Criterion 10)
Pregnant or lactating, or intending to become pregnant during the study
Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol,
Malignancies other than the one studied in this protocol within 5 years prior to Cycle 1, Day 1
Significant cardiovascular disease, such as New York Heart Association cardiac disease more than Class III, myocardial infarction within 3 months, unstable arrhythmias, or unstable angina, renal disorder
Signs or symptoms of severe infection within 2 weeks prior to initiation of study treatment
Major surgical procedure within 4 weeks prior to study treatment initiation or anticipation of need for a major surgical procedure during the course of the study other than for diagnosis
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins, history of autoimmune disease are allowed if controlled and on stable treatment (i.e., same treatment, same dose) for the last 12 weeks. History of idiopathic pulmonary fibrosis evidence of active pneumonitis on screening chest (CT) scan
Known hypersensitivity or allergy to biopharmaceuticals or any component of the atezolizumab formulation, Prior allogeneic stem cell or solid organ transplantation
Patients with active hepatitis B (defined as having a positive hepatitis B surface antigen [HBsAg] test at screening) or hepatitis C
Active tuberculosis
Administration of a live, attenuated vaccine within 4 weeks prior to study treatment initiation.
Prior treatment with CD137 agonists or immune checkpoint blockade therapies
Treatment with systemic immunostimulatory agents within 4 weeks or five half-lives of the drug, whichever is shorter, prior to initiation of study treatment
Specifically for patients without autoimmune disease: treatment with systemic corticosteroids or other systemic immunosuppressive medications within 2 weeks prior to study treatment initiation or anticipated requirement for systemic immunosuppressive medications during the study treatment period.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary objective of this study is to evaluate the safety of atezolizumab based on the following endpoints: <br/ ><br>1) Nature, severity, duration, frequency and timing of adverse events (AEs) <br/ ><br>2) Changes in vital signs, physical findings, and clinical laboratory results during and following atezolizumab administrationTimepoint: The primary objective of this study is to evaluate the safety of atezolizumab based on the following endpoints: <br/ ><br>1) Nature, severity, duration, frequency and timing of adverse events (AEs) <br/ ><br>2) Changes in vital signs, physical findings, and clinical laboratory results during and following atezolizumab administration
- Secondary Outcome Measures
Name Time Method 1)The secondary objectives of the study include evaluation of the efficacy of atezolizumab based on OS, ORR, PFS, DCR and DoR <br/ ><br>2) Evaluation of efficacy of atezolizumab according to the following patient-reported outcomes (PROs; Appendix 4): <br/ ><br>· Change from baseline in health-related quality of life (HRQoL), as assessed using the EORTC Quality-of-Life Questionnaire Core 30 (QLQ-C30) <br/ ><br>· EuroQol EQ-5D-5L-assessed utility <br/ ><br>Timepoint: The primary objective of this study is to evaluate the safety of atezolizumab based on the following endpoints: <br/ ><br>1) Nature, severity, duration, frequency and timing of adverse events (AEs) <br/ ><br>2) Changes in vital signs, physical findings, and clinical laboratory results during and following atezolizumab administration